HEALTHEURACTIV
Dutch drug reimbursement reform stalls despite rising patient waits [Advocacy Lab]
The Dutch drug reimbursement reform has stalled despite increasing patient wait times. The Dutch health ministry faces criticism over the delay but expresses hope that the industry will work constructively within the new framework.
Mentioned
Related Signal
Adjacent reporting
- Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting
- Nearly 42million patients waited too long for hospital treatment as NHS missed key target for a decade
- NHS hits interim 18-week waiting time target for first time in years... but 7.1 MILLION people are still waiting for routine treatment
- Hospital waiting times in England have improved, Streeting says
- FDA delays cost Americans trillions and slow lifesaving drugs, new report says
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more